Developer docs
API playgroundTry for free, no card

Search company profiles

Diorasis Therapeutics

Full company profile

uuid0009pfd

Namestring
Diorasis Therapeutics
Legal namestring
Diorasis Therapeutics Corporation
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Diorasis Therapeutics is a pre-clinical stage privately held US biotech company developing a first-in-class disease-modifying gene therapy for open angle glaucoma (OAG), the leading cause of irreversible blindness worldwide. The company's core asset is an AAV vector that delivers an engineered enzymatically inactive tissue plasminogen activator (EI-tPA) variant to trabecular meshwork cells via a single intracameral injection, upregulating multiple matrix metalloproteinases (MMPs) to remodel extracellular matrix, restore aqueous humor outflow, and lower intraocular pressure (IOP) long-term — potentially for life. Critically, the therapy is gene-agnostic, meaning it is intended to be applicable to all OAG patients with elevated IOP regardless of genetic background, and it avoids lowering IOP in normal eyes, mitigating hypotony risk.

The company's scientific foundation is rooted in more than 20 years of award-winning glaucoma research conducted by co-founder John Danias at Mt. Sinai and SUNY, which established the role of the fibrinolytic pathway in outflow facility regulation. The asset is currently in IND-enabling safety and toxicology studies. The Scientific Advisory Board includes Dirk Sauer (33+ years pharma R&D), Kuldev Singh, Jeffrey Liebmann (clinical ophthalmology), and Alfred S. Lewin (gene therapy). Peer-reviewed publications in PLoS One, Experimental Eye Research, and Molecular Vision demonstrate decreased IOP in steroid-induced glaucoma models in mice and sheep.

The company has not yet commercialized any product, has no disclosed revenue, and operates on a pre-commercial biotech model. Its go-to-market strategy is expected to be partnership- or licensing-driven with major pharmaceutical companies for global commercialization, with possible direct commercialization to glaucoma specialists and ophthalmologists in select markets. The addressable market is large — approximately 2.7 million Americans and 57.5 million patients worldwide have open angle glaucoma, with the US spending approximately $2.86 billion annually on glaucoma care and 300,000 new US patients diagnosed each year. No external venture financing rounds, institutional investors, or parent company have been disclosed; ownership is founder-driven (Remis Bistras as CEO, John Danias, and Kali Stasi).

Short descriptiontext

Diorasis Therapeutics is a pre-clinical US biotech developing a first-in-class AAV gene therapy that delivers an engineered EI-tPA variant to the trabecular meshwork via a single intracameral injection to lower intraocular pressure long-term in open angle glaucoma patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
gene therapy, ophthalmic therapeutics, glaucoma treatment, AAV vector delivery, biopharmaceutical research
Industry2 codes
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code1 code
  • Scientific Research and Development Services5417
Product category
Ophthalmic Gene Therapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Product Commercialization
TypeOne Time License
Description

Pre-clinical stage biotech company developing first-in-class disease-modifying gene therapy for open angle glaucoma. Revenue will be generated through commercialization of the lead compound upon regulatory approval, likely through partnering/licensing deals with major pharmaceutical companies or direct commercialization to ophthalmologists and glaucoma specialists.

diorasistherapeutics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Diorasis Therapeutics is developing a first-in-class, disease-modifying gene therapy for open angle glaucoma using an AAV vector to deliver an engineered EI-tPA variant via a single intracameral injection. The therapy targets the root cause of elevated intraocular pressure by restoring trabecular meshwork function through MMP modulation, with the intent of replacing chronic eye-drop regimens. The lead compound is intended for eventual out-licensing or partnership with major pharmaceutical companies following pre-clinical and clinical milestones.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Single administration provides long-term (potentially life-long) IOP reduction
+2 more records
Product overview1 text field

Diorasis Therapeutics is a pre-clinical stage biotech company developing a single first-in-class disease-modifying gene therapy product for open angle glaucoma. The lead compound is an AAV-delivered enzymatically-inactive tissue plasminogen activator (EI-tPA) variant administered via a single intracameral injection. The therapy targets the trabecular meshwork to improve outflow facility and decrease intraocular pressure long-term, potentially for life. The company is currently conducting IND-enabling safety and toxicology experiments.

Product and service1 record
1EI-tPA AAV Gene Therapy for Open Angle Glaucoma
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partnership based on more than 20 years of award-winning glaucoma research conducted in John Danias' laboratory at Mt. Sinai. This foundational research established the role of fibrinolytic pathway components including tPA in regulation of outflow facility and identified tissue plasminogen activator (tPA) as an important regulator of outflow facility.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with SUNY based on 20+ years of award-winning glaucoma research. The foundational science behind the company's gene therapy technology originated from research conducted at SUNY.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage AAV-based gene therapy company targeting ophthalmology (wet AMD, diabetic retinopathy). Directly comparable to Diorasis as a fellow AAV gene therapy developer focused on high-prevalence eye diseases with single-injection profiles.

TypeDirect peer
Description

Leading AAV gene therapy platform company with multiple ophthalmology programs (wet AMD, diabetic retinopathy). Comparable as an AAV-based gene therapy developer in ophthalmology with a similar scientific and regulatory pathway.

TypeDirect peer
Description

Clinical-stage gene therapy company with ophthalmology programs (choroideremia, wet AMD) using engineered AAV capsids. Comparable therapeutic modality (single-dose AAV gene therapy) and target disease space (irreversible vision loss).

TypeDirect peer
Description

Clinical-stage gene therapy company with multiple ophthalmology programs including X-linked retinitis pigmentosa and achromatopsia. Comparable as a single-asset/single-indication gene therapy developer in inherited and acquired eye diseases.

TypeDirect peer
Description

Was a clinical-stage gene therapy company developing GT005 for geographic atrophy AMD (acquired by Novartis in 2021 for $1.5B). Direct comparable for an ocular gene therapy company whose strategic value was recognized through major pharma acquisition.

TypeDirect peer
Description

Clinical-stage gene therapy company developing optogenetic therapies for retinal diseases (RP, Stargardt). Comparable single-injection ocular gene therapy approach with focus on common, irreversible blinding conditions.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company developing treatments for inherited retinal diseases (X-linked retinitis pigmentosa, achromatopsia). Comparable scientific platform and therapeutic area focus.

TypeEmerging player
Description

Clinical-stage gene therapy and biologics company with ophthalmology programs targeting wet AMD and other retinal diseases. Comparable as a fellow emerging ocular gene therapy developer with a focus on partnership-driven commercialization.

TypeBroad incumbent
Description

Was a commercial-stage glaucoma-focused pharmaceutical company (acquired by Alcon for $770M in 2020) with several approved IOP-lowering products. Comparable as a glaucoma-focused company, though operating in pharmacological rather than gene therapy modality.

TypeBroad incumbent
Description

Pioneer in ocular gene therapy (developer of Luxturna for RPE65-mediated inherited retinal disease, acquired by Roche for $4.8B in 2019). Sets the benchmark for ophthalmic gene therapy commercialization, regulatory pathway, and strategic value.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Diorasis Therapeutics

Ophthalmic Gene Therapydiorasistherapeutics.com

Diorasis Therapeutics is a pre-clinical US biotech developing a first-in-class AAV gene therapy that delivers an engineered EI-tPA variant to the trabecular meshwork via a single intracameral injection to lower intraocular pressure long-term in open angle glaucoma patients.

What Diorasis Therapeutics does

Diorasis Therapeutics is a pre-clinical stage privately held US biotech company developing a first-in-class disease-modifying gene therapy for open angle glaucoma (OAG), the leading cause of irreversible blindness worldwide. The company's core asset is an AAV vector that delivers an engineered enzymatically inactive tissue plasminogen activator (EI-tPA) variant to trabecular meshwork cells via a single intracameral injection, upregulating multiple matrix metalloproteinases (MMPs) to remodel extracellular matrix, restore aqueous humor outflow, and lower intraocular pressure (IOP) long-term — potentially for life. Critically, the therapy is gene-agnostic, meaning it is intended to be applicable to all OAG patients with elevated IOP regardless of genetic background, and it avoids lowering IOP in normal eyes, mitigating hypotony risk.

The company's scientific foundation is rooted in more than 20 years of award-winning glaucoma research conducted by co-founder John Danias at Mt. Sinai and SUNY, which established the role of the fibrinolytic pathway in outflow facility regulation. The asset is currently in IND-enabling safety and toxicology studies. The Scientific Advisory Board includes Dirk Sauer (33+ years pharma R&D), Kuldev Singh, Jeffrey Liebmann (clinical ophthalmology), and Alfred S. Lewin (gene therapy). Peer-reviewed publications in PLoS One, Experimental Eye Research, and Molecular Vision demonstrate decreased IOP in steroid-induced glaucoma models in mice and sheep.

The company has not yet commercialized any product, has no disclosed revenue, and operates on a pre-commercial biotech model. Its go-to-market strategy is expected to be partnership- or licensing-driven with major pharmaceutical companies for global commercialization, with possible direct commercialization to glaucoma specialists and ophthalmologists in select markets. The addressable market is large — approximately 2.7 million Americans and 57.5 million patients worldwide have open angle glaucoma, with the US spending approximately $2.86 billion annually on glaucoma care and 300,000 new US patients diagnosed each year. No external venture financing rounds, institutional investors, or parent company have been disclosed; ownership is founder-driven (Remis Bistras as CEO, John Danias, and Kali Stasi).

Diorasis Therapeutics firmographics

Firmographics
Name
Diorasis Therapeutics
Legal name
Diorasis Therapeutics Corporation
Website
https://diorasistherapeutics.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Diorasis Therapeutics is a pre-clinical US biotech developing a first-in-class AAV gene therapy that delivers an engineered EI-tPA variant to the trabecular meshwork via a single intracameral injection to lower intraocular pressure long-term in open angle glaucoma patients.
Ownership category
akta.pro rank

Diorasis Therapeutics industry classification

Industry
Product category
Ophthalmic Gene Therapy
NAICS
Scientific Research and Development Services (5417)
akta.pro industry
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Gene therapy
  • Ophthalmic therapeutics
  • Glaucoma treatment
  • AAV vector delivery
  • Biopharmaceutical research

Where Diorasis Therapeutics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Markets served

Diorasis Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Gene Therapy Product Commercialization: Pre-clinical stage biotech company developing first-in-class disease-modifying gene therapy for open angle glaucoma. Revenue will be generated through commercialization of the lead compound upon regulatory approval, likely through partnering/licensing deals with major pharmaceutical companies or direct commercialization to ophthalmologists and glaucoma specialists.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Diorasis Therapeutics product offering

Product offering

Core offering

Diorasis Therapeutics is developing a first-in-class, disease-modifying gene therapy for open angle glaucoma using an AAV vector to deliver an engineered EI-tPA variant via a single intracameral injection. The therapy targets the root cause of elevated intraocular pressure by restoring trabecular meshwork function through MMP modulation, with the intent of replacing chronic eye-drop regimens. The lead compound is intended for eventual out-licensing or partnership with major pharmaceutical companies following pre-clinical and clinical milestones.

Product overview

Diorasis Therapeutics is a pre-clinical stage biotech company developing a single first-in-class disease-modifying gene therapy product for open angle glaucoma. The lead compound is an AAV-delivered enzymatically-inactive tissue plasminogen activator (EI-tPA) variant administered via a single intracameral injection. The therapy targets the trabecular meshwork to improve outflow facility and decrease intraocular pressure long-term, potentially for life. The company is currently conducting IND-enabling safety and toxicology experiments.

Differentiator

Problem solved

Functional benefit

Products and services

  • EI-tPA AAV Gene Therapy for Open Angle Glaucoma

Quantifiable outcome

  • Single administration provides long-term (potentially life-long) IOP reduction
  • +2 more outcomes

Companies that use Diorasis Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Diorasis Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Diorasis Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Mt. Sinai (John Danias Lab)coreStrategic or Co-development PartnerResearch partnership based on more than 20 years of award-winning glaucoma research conducted in John Danias' laboratory at Mt. Sinai. This foundational research established the role of fibrinolytic pathway components including tPA in regulation of outflow facility and identified tissue plasminogen activator (tPA) as an important regulator of outflow facility.
  • SUNYcoreStrategic or Co-development PartnerResearch collaboration with SUNY based on 20+ years of award-winning glaucoma research. The foundational science behind the company's gene therapy technology originated from research conducted at SUNY.

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Diorasis Therapeutics competitors and assessment

Company assessment

Direct peers

  • Adverum Biotechnologies: Clinical-stage AAV-based gene therapy company targeting ophthalmology (wet AMD, diabetic retinopathy). Directly comparable to Diorasis as a fellow AAV gene therapy developer focused on high-prevalence eye diseases with single-injection profiles.
  • REGENXBIO: Leading AAV gene therapy platform company with multiple ophthalmology programs (wet AMD, diabetic retinopathy). Comparable as an AAV-based gene therapy developer in ophthalmology with a similar scientific and regulatory pathway.
  • 4D Molecular Therapeutics: Clinical-stage gene therapy company with ophthalmology programs (choroideremia, wet AMD) using engineered AAV capsids. Comparable therapeutic modality (single-dose AAV gene therapy) and target disease space (irreversible vision loss).
  • MeiraGTx: Clinical-stage gene therapy company with multiple ophthalmology programs including X-linked retinitis pigmentosa and achromatopsia. Comparable as a single-asset/single-indication gene therapy developer in inherited and acquired eye diseases.
  • Gyroscope Therapeutics: Was a clinical-stage gene therapy company developing GT005 for geographic atrophy AMD (acquired by Novartis in 2021 for $1.5B). Direct comparable for an ocular gene therapy company whose strategic value was recognized through major pharma acquisition.
  • Nanoscope Therapeutics: Clinical-stage gene therapy company developing optogenetic therapies for retinal diseases (RP, Stargardt). Comparable single-injection ocular gene therapy approach with focus on common, irreversible blinding conditions.
  • Applied Genetic Technologies Corporation (AGTC): Clinical-stage AAV gene therapy company developing treatments for inherited retinal diseases (X-linked retinitis pigmentosa, achromatopsia). Comparable scientific platform and therapeutic area focus.

Emerging players

  • Ocugen: Clinical-stage gene therapy and biologics company with ophthalmology programs targeting wet AMD and other retinal diseases. Comparable as a fellow emerging ocular gene therapy developer with a focus on partnership-driven commercialization.

Broad incumbents

  • Aerie Pharmaceuticals: Was a commercial-stage glaucoma-focused pharmaceutical company (acquired by Alcon for $770M in 2020) with several approved IOP-lowering products. Comparable as a glaucoma-focused company, though operating in pharmacological rather than gene therapy modality.
  • Spark Therapeutics: Pioneer in ocular gene therapy (developer of Luxturna for RPE65-mediated inherited retinal disease, acquired by Roche for $4.8B in 2019). Sets the benchmark for ophthalmic gene therapy commercialization, regulatory pathway, and strategic value.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Diorasis Therapeutics social profiles

Digital presence

Diorasis Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Diorasis Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Diorasis Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Diorasis Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diorasis Therapeutics

What does Diorasis Therapeutics do?

Diorasis Therapeutics is developing a first-in-class, disease-modifying gene therapy for open angle glaucoma using an AAV vector to deliver an engineered EI-tPA variant via a single intracameral injection. The therapy targets the root cause of elevated intraocular pressure by restoring trabecular meshwork function through MMP modulation, with the intent of replacing chronic eye-drop regimens. The lead compound is intended for eventual out-licensing or partnership with major pharmaceutical companies following pre-clinical and clinical milestones.

Is Diorasis Therapeutics a public or private company?

Diorasis Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Diorasis Therapeutics founded?

Diorasis Therapeutics was founded in 2022. It employs 1 to 10 people.

Where is Diorasis Therapeutics based?

Diorasis Therapeutics is headquartered in Watertown, United States, in the North America region.

How does Diorasis Therapeutics make money?

One revenue line is on record: gene Therapy Product Commercialization.

Who are Diorasis Therapeutics's main competitors?

Direct peers on record are Adverum Biotechnologies, REGENXBIO, 4D Molecular Therapeutics, MeiraGTx, Gyroscope Therapeutics, Nanoscope Therapeutics and Applied Genetic Technologies Corporation (AGTC). Ocugen is listed as an emerging player. Broad incumbents are Aerie Pharmaceuticals and Spark Therapeutics.

Does Diorasis Therapeutics have an API?

No public API is recorded for Diorasis Therapeutics.

What industry is Diorasis Therapeutics in?

Diorasis Therapeutics's product category is Ophthalmic Gene Therapy. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 5417.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals